Research Analysts’ Weekly Ratings Updates for Apollomics (APLM)

Apollomics (NASDAQ: APLM) recently received a number of ratings updates from brokerages and research firms:

• 12/1/2025 – Apollomics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Apollomics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/22/2025 – Apollomics was upgraded by analysts at Wall Street Zen to a “sell” rating.
• 11/19/2025 – Apollomics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – Apollomics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.